CanSinoBIO CEO attends World Economic Forum meetings in New York
The company said first-half revenue rose 43.8% to RMB 550 million and overseas revenue reached RMB 152 million. It also cited vaccine authorization and pipeline updates.
The company said first-half revenue rose 43.8% to RMB 550 million and overseas revenue reached RMB 152 million. It also cited vaccine authorization and pipeline updates.